Guided Therapeutics (GTHP) Retained Earnings (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Retained Earnings data on file, last reported at -$157.1 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 210.21% year-over-year to -$157.1 million; the trailing twelve-month figure through Dec 2025 stood at -$157.1 million (down 210.21% YoY), and the FY2025 full-year result was -$157.1 million, down 210.21% from the prior year.
• Retained Earnings declined to -$157.1 million in Q4 2025, from $145.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $145.2 million in Q3 2025 to a low of -$157.1 million in Q4 2025.
• A 5-year average of $24.1 million and a median of $131.6 million in 2021 frame the typical range for Retained Earnings.
• Peak annual rise in Retained Earnings reached 20160.33% in 2021, while the deepest fall reached 5760.64% in 2021.
• Tracing GTHP's Retained Earnings over 5 years: stood at $126.8 million in 2021, then climbed by 8.9% to $138.1 million in 2022, then advanced by 2.1% to $141.0 million in 2023, then rose by 1.08% to $142.5 million in 2024, then sank by 210.21% to -$157.1 million in 2025.
• Business Quant data shows GTHP's Retained Earnings at -$157.1 million in Q4 2025, $145.2 million in Q3 2025, and $144.0 million in Q2 2025.